Spike Medicine 22
  • Home

  • About Us

      • Company Profile

      • Enterprise culture

      • Qualification Honor

      • Chairman's Speech

  • News

      • Company Dynamics

      • Industry dynamics

  • Recruitment

  • Contact Us

      • Contact Information

      • Online message

  • Home

  • About Us

    • Company Profile

    • Enterprise culture

    • Qualification Honor

    • Chairman's Speech

  • News

    • Company Dynamics

    • Industry dynamics

  • Recruitment

  • Contact Us

    • Contact Information

    • Online message

+86-579-82131973
中文
NEWS

Dec 10,2017

Review of 41 New Drugs Approved by FDA in 2017


Key words:

Review of 41 New Drugs Approved by FDA in 2017

Dec 10,2017

Up to now, CDER has approved 41 new molecular entities, and the PDUFA deadline for 2 drugs falls in December. If FDA does not speed up the approval of new drugs in December, the number of new molecular entities approved in 2017 may be 41-43. Of course, the new drugs covered in this article are NDA or BLA accepted by CDER, and do not include CBER-reviewed varieties, such as CAR-T products. Compared with last year's 20 or so, this year is a bumper year. Of the 41 products that have been approved, 31 are approved for the first time in the world, 19 products have received priority review (P),13 have received breakthrough therapy certification (B),17 have received orphan drug qualification (O), and only 11 products except biological products are subject to standard review (O)


Key words:

Up to now, CDER has approved 41 new molecular entities, and the PDUFA deadline for 2 drugs falls in December. If FDA does not speed up the approval of new drugs in December, the number of new molecular entities approved in 2017 may be 41-43. Of course, the new drugs covered in this article are NDA or BLA accepted by CDER, and do not include CBER-reviewed varieties, such as CAR-T products. Compared with last year's 20 or so, this year is a bumper year. Of the 41 products that have been approved, 31 are approved for the first time in the world, 19 products have received priority review (P),13 have received breakthrough therapy certification (B),17 have received orphan drug qualification (O), and only 11 products except biological products are subject to standard review (O)

Dec 10,2017

Online sales of prescription drugs to open up hopeless pharmaceutical e-commerce or meet the "life and death robbery"


Key words:

Online sales of prescription drugs to open up hopeless pharmaceutical e-commerce or meet the "life and death robbery"

Dec 10,2017

China's pharmaceutical industry is in a new initial stage


Key words:

China's pharmaceutical industry is in a new initial stage

Dec 15,2017

Traditional Chinese medicine injection, unreasonable use magnifies the safety risk.


Key words:

Traditional Chinese medicine injection, unreasonable use magnifies the safety risk.

Dec 15,2017

Health Planning Commission: Chinese medicine clinics shall not provide western medicine and western medicine services.


Key words:

Health Planning Commission: Chinese medicine clinics shall not provide western medicine and western medicine services.
< 1...373839...61 >
contact Contact
tel +86-579-82131973
tel gs@zjifyy.com.cn
Whatsapp
top TOP
Chenglian Medicine

Follow us

  • Home

  • About Us

    • Company Profile

    • Enterprise culture

    • Qualification Honor

    • Chairman's Speech

  • News

    • Company Dynamics

    • Industry dynamics

  • Recruitment

  • Contact Us

    • Contact Information

    • Online message

Zhejiang Jianfeng Pharmaceutical Co., Ltd.

Sales Line:

+86-579-82131973
Mailbox:gs@zjifyy.com.cn
Company address: No.88, Wujiang East Road, Jinhua City, Zhejiang Province

Copyright©2023 Zhejiang Jianfeng Pharmaceutical Co., Ltd

Powered by www.300.cn | SEO  | Business License

SAF Coolest v1.3.1.1 设置面板XRBSX-ZEJN-JAAZE-ZWD

图片ALT信息: JIANFENG

无数据提示

Sorry, the current column is being updated, please look forward to it!

You can view other columns or returnHome Page